Posted by Michael Wonder on 04 Nov 2020
NICE updates guidance for nivolumab for melanoma
4 November 2020 - NICE has updated its guidance for nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease.
Nivolumab is not recommended, within its marketing authorisation, for the adjuvant treatment of melanoma with lymph node involvement or metastatic disease that has been completely resected in adults.
Clinical evidence shows that nivolumab improves survival without the cancer coming back (recurrence-free survival) compared with ipilimumab. There are currently no trials comparing nivolumab with standard care in the NHS.
